CTLA4 and cancer: Nowadays, immunotherapy is a main option for cancer therapy [29, 30], particularly immune checkpoint blockade (ICB) targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and PD-1 [31].